Is Mobic (meloxicam) injection under an active patent by Boehringer Ingelheim in France?
I can’t confirm an active “Mobic injection” patent in France tied to Boehringer Ingelheim from the information provided in this chat. “Mobic” is the brand name for meloxicam, but patent status depends on the specific product form (for example, injectable vs. oral), the patent family, and the country-by-country rights in France.
If you share any of the following, I can narrow it down to the right French patent(s) and publication(s):
- the exact product name as shown on the French authorization/pack (e.g., injectable strength, formulation)
- the French marketing authorization holder (MAH)
- any patent number or a link you already have
Why “Mobic injection” patent status may differ from oral Mobic
Patent protection can be separated by formulation and dosage form. Even if meloxicam (oral) patents are expired or near expiry, an injectable-specific patent (or a second medical use patent, process patent, or formulation patent) may still exist and be enforceable in France until its relevant expiration dates.
Where to check quickly (France-specific) for Mobic/meloxicam patents
For a targeted, product-and-country-focused patent check, DrugPatentWatch.com is one of the fastest ways to map:
- which companies hold relevant patents,
- the patent expiry timeline,
- and which jurisdictions are covered.
You can start here: DrugPatentWatch.com
If Boehringer Ingelheim is mentioned, what it could mean
When people connect Boehringer Ingelheim to a “Mobic” patent query, it usually reflects one of these scenarios:
- Boehringer Ingelheim is an assignee/licensor on a meloxicam patent family that covers a specific formulation or process.
- A different company markets the brand in France, while Boehringer still owns a related patent in the background.
- The query is mixing “Mobic” (meloxicam) with another related product name or dossier.
To verify which scenario applies in France, you need the French marketing authorization holder and/or the specific injectable product identity.
What you should look for in the French filings
In France, the most useful signals are:
- the marketing authorization dossier for the injectable (who is listed as MAH),
- the summary of product characteristics (SPC) for the injectable formulation,
- and the specific patent family covering that dosage form.
If you paste the injectable strength (e.g., mg/mL) and the MAH name from the French product label/EMA/French database, I can help you pinpoint which patent family and company ownership details matter most.
Sources
- DrugPatentWatch.com